Yes, you can stent a bypass graft. When a bypass graft narrows or becomes blocked after surgery, cardiologists can thread a catheter to the graft and place a stent inside it, just as they would in a native coronary artery. This is a well-established procedure, though it carries some unique risks compared to stenting a regular artery, and current guidelines actually prefer a different approach when possible.
How Graft Stenting Works
The procedure is essentially the same as any other coronary stent placement. A catheter is guided from an artery in the wrist or groin up to the heart, a balloon is inflated inside the narrowed graft to open it up, and a metal stent is left in place to hold the graft open. Angiographic success rates are high, around 92.5% in studies of saphenous vein graft interventions.
The key difference is which graft is involved. Most bypass surgeries use two types of blood vessels: the internal mammary artery (taken from the chest wall) and saphenous veins (taken from the leg). Internal mammary artery grafts rarely need stenting because they have excellent long-term patency, around 96.6% at one year for the left internal mammary artery. Saphenous vein grafts are far more prone to disease over time and account for the vast majority of graft stenting procedures.
Why Doctors Often Prefer Stenting the Original Artery
Here’s something that surprises many patients: when a vein graft fails, current guidelines recommend stenting the original blocked coronary artery (the one the graft was bypassing) rather than stenting the graft itself. The PROCTOR trial, the first randomized study to compare these two strategies head-to-head, was designed specifically to test whether going after the native artery produces better outcomes than fixing the graft.
The reasoning is straightforward. Saphenous vein grafts develop a different kind of disease than native arteries. Their walls accumulate soft, crumbly plaque that breaks apart easily when disturbed by a balloon or stent. If the original artery can be reached and opened, it tends to be a safer and more durable target. That said, the native artery isn’t always accessible. It may be completely calcified or occluded in a way that makes intervention impossible, in which case stenting the graft becomes the best option.
The Biggest Risk: Distal Embolization
The defining complication of vein graft stenting is distal embolization, where fragments of plaque break loose during the procedure and travel downstream, plugging smaller vessels in the heart muscle. This occurred in about 7.5% of patients in studies of vein graft interventions. When severe, it causes what’s called “no-reflow,” where blood essentially stops flowing through the treated vessel despite the stent being successfully placed. No-reflow and slow flow together affected 7.5% of patients in the same data.
To reduce this risk, doctors use embolic protection devices during most vein graft interventions. These are small filters or balloons placed beyond the blockage to catch debris before it reaches the heart muscle. The FDA recognizes these devices specifically for use during saphenous vein bypass graft interventions, and their use is considered standard practice for graft stenting.
Drug-Eluting vs. Bare-Metal Stents in Grafts
In native coronary arteries, drug-eluting stents (which slowly release medication to prevent scar tissue from regrowing) have largely replaced bare-metal stents because they significantly reduce the chance of re-narrowing. In bypass grafts, the story is different. A meta-analysis of seven studies covering 1,639 patients found that drug-eluting stents showed no meaningful advantage over bare-metal stents in vein grafts. Rates of death, heart attack, and the need for repeat procedures were statistically similar between the two types over an average follow-up of 32 months.
This is an unusual finding that likely reflects the unique biology of vein graft disease. The mechanisms that cause grafts to fail again after stenting are different from those in native arteries, so the drug coating that works well in one setting doesn’t translate to the other.
Stenting vs. Redo Bypass Surgery
When a graft fails, the other major option is repeat bypass surgery. This is a much bigger operation than the first time around, carrying two to five times the mortality risk of the original bypass. The higher risk comes from scar tissue from the first surgery, the technical difficulty of working around existing grafts, and the fact that patients are older and often sicker by the time a graft fails.
Stenting has a clear advantage in the immediate postoperative period: lower mortality and a dramatically shorter recovery. A graft stenting procedure typically requires only an overnight hospital stay, sometimes just a same-day discharge, compared to 6 to 12 weeks of full recovery after redo bypass surgery. Long-term survival rates, however, are similar between the two approaches. Patients who undergo redo surgery are less likely to need additional procedures down the road, but they accept greater upfront risk to get there.
For most patients with a failed graft today, the first-line approach is catheter-based intervention, either stenting the native artery or the graft itself. Redo bypass surgery is generally reserved for patients with extensive disease affecting multiple grafts or vessels, where stenting alone can’t adequately restore blood flow.
What Recovery Looks Like
Recovery from graft stenting is similar to any other stent procedure. Most patients go home the same day or the next morning. You’ll be asked to avoid heavy lifting for a few days and will start blood-thinning medications to prevent clots from forming inside the new stent. Follow-up appointments typically include imaging or stress testing within the first few months to confirm the stent is holding open.
The longer-term concern is that stented vein grafts have a meaningful re-narrowing rate. Vein grafts are inherently more prone to disease progression than arteries, so even a successful stent placement doesn’t reset the clock entirely. Many patients with stented grafts will need ongoing monitoring and, in some cases, additional interventions over the following years.